pharmaphorum2h
FDA starts review of first bronchiectasis drug candidate
The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...
The Pharma Letter17h
FDA Priority Review for Insmed's brensocatib for bronchiectasis
The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with ...
Insmed price target raised to $92 from $83 at JPMorgan
JPMorgan raised the firm’s price target on Insmed (INSM) to $92 from $83 and keeps an Overweight rating on the shares. The firm sees 2025 ...
pharmaphorum1h
MSD starts pivotal trial of ROR1 drug in first-line lymphoma
MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...
‘Unstoppable’ seven-year-old fundraises for Sheffield Children’s
Seven-year-old Harmony from Sheffield is supporting The Children’s Hospital Charity by taking part in Theo’s Pyjama Day in ...
Medindia8h
Global Airway Clearance Devices for Cystic Fibrosis Market to Show Positive Growth at a CAGR of ~5% by 2032 | DelveInsight
DelveInsight's Airway Clearance Devices for Cystic Fibrosis Market Insights report provides the current and forecast market analysis, indiv ...
manilatimes13h
Nuance Pharma Announces Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China
Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients ...